Analysts at Numis Reiterated their “Buy” rating for Indivior Plc (LON:INDV) with GBX 640.00 Target; Insmed (INSM) Has 3.74 Sentiment

February 15, 2018 - By Hazel Jackson

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company has market cap of $1.94 billion. The companyÂ’s lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It currently has negative earnings. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension.

The company have set PT of GBX 640.00 on Indivior Plc (LON:INDV) shares. This is 74.51% from the current price. In analysts report revealed to clients and investors on Thursday morning, Numis kept their “Buy” rating on shares of INDV.

The stock decreased 8.76% or GBX 35.47 during the last trading session, reaching GBX 369.43. About 907,650 shares traded. Indivior PLC (LON:INDV) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Indivior PLC, together with its subsidiaries, develops, makes, and sells buprenorphine prescription drugs for the treatment of opioid dependence worldwide. The company has market cap of 2.67 billion GBP. The company's product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue, and CNS disorders/schizophrenia. It has a 9.72 P/E ratio. It markets and promotes SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.

Among 8 analysts covering Indivior Plc (LON:INDV), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Indivior Plc has GBX 640 highest and GBX 140 lowest target. GBX 471.88’s average target is 27.73% above currents GBX 369.43 stock price. Indivior Plc had 112 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, October 4 by Deutsche Bank. The rating was maintained by Stifel Nicolaus with “Buy” on Monday, July 11. The stock of Indivior PLC (LON:INDV) has “Buy” rating given on Friday, April 29 by Deutsche Bank. As per Monday, November 7, the company rating was maintained by Jefferies. The stock has “Buy” rating by Deutsche Bank on Monday, November 30. Deutsche Bank maintained Indivior PLC (LON:INDV) rating on Wednesday, November 25. Deutsche Bank has “Buy” rating and GBX 300 target. Cantor Fitzgerald maintained the stock with “Hold” rating in Monday, June 6 report. Cantor Fitzgerald maintained Indivior PLC (LON:INDV) rating on Wednesday, February 22. Cantor Fitzgerald has “Hold” rating and GBX 300 target. The stock has “Buy” rating by Jefferies on Friday, November 6. The stock of Indivior PLC (LON:INDV) has “Buy” rating given on Thursday, November 3 by Numis Securities.

Palo Alto Investors Llc holds 8.11% of its portfolio in Insmed Incorporated for 6.17 million shares. Foresite Capital Management Ii Llc owns 300,000 shares or 3.8% of their US portfolio. Moreover, Redmile Group Llc has 3.07% invested in the company for 1.99 million shares. The New York-based Ghost Tree Capital Llc has invested 2.15% in the stock. Ra Capital Management Llc, a Massachusetts-based fund reported 722,714 shares.

Analysts await Insmed Incorporated (NASDAQ:INSM) to report earnings on February, 22. They expect $-0.66 earnings per share, up 40.00% or $0.44 from last year’s $-1.1 per share. After $-0.69 actual earnings per share reported by Insmed Incorporated for the previous quarter, Wall Street now forecasts -4.35% EPS growth.

The stock increased 4.86% or $1.17 during the last trading session, reaching $25.26. About 743,592 shares traded. Insmed Incorporated (INSM) has risen 57.88% since February 15, 2017 and is uptrending. It has outperformed by 41.18% the S&P500.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>